Camlipixant Explained

Legal Status:

Investigational

Cas Number:

1621164-74-6

Pubchem:

76955630

Iuphar Ligand:

11232

Drugbank:

DB19217

Unii:

TB7D2H7MZZ

Kegg:

D12785

Chembl:

5095035

Synonyms:

BLU-5937

Iupac Name:

methyl (2S)-2-2-[2,6-difluoro-4-(methylcarbamoyl)phenyl]-7-methylimidazo[1,2-a]pyridin-3-ylmethyl]morpholine-4-carboxylate| C=23 | H=24 | F=2 | N=4 | O=4| SMILES = CC1=CC2=NC(=C(N2C=C1)C[C@H]3CN(CCO3)C(=O)OC)C4=C(C=C(C=C4F)C(=O)NC)F| StdInChI = 1S/C23H24F2N4O4/c1-13-4-5-29-18(11-15-12-28(6-7-33-15)23(31)32-3)21(27-19(29)8-13)20-16(24)9-14(10-17(20)25)22(30)26-2/h4-5,8-10,15H,6-7,11-12H2,1-3H3,(H,26,30)/t15-/m0/s1| StdInChIKey = SEHLMRJSQFAPCJ-HNNXBMFYSA-N}}Camlipixant is an investigational new drug that is being evaluated for the treatment of chronic cough.^[1] It is a P2X3 receptor antagonist.^[2]

See also

• gefapixant

References

Notes and References

1. Web site: Camlipixant - BELLUS Health . AdisInsight . Springer Nature Switzerland AG .
2. Garceau D, Chauret N . BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration . Pulmonary Pharmacology & Therapeutics . 56 . 56–62 . June 2019 . 30902655 . 10.1016/j.pupt.2019.03.007 .